Shares of HUTCHMED (00013) climbed more than 3% during the final stretch of Hong Kong trading on Wednesday, reflecting renewed investor confidence in the biopharmaceutical firm's overseas growth strategy.
At the time of writing, the stock was up 2.72% at HK$21.90, with turnover reaching HK$90.57 million on the exchange.
Sentiment was buoyed by the company's announcement on September 3 regarding an exclusive licensing agreement with GSK for HMPL-A830, a KRAS-EGFR antibody-targeted therapy conjugate (ATTC). Under the terms of the deal, GSK will secure overseas rights in exchange for an upfront payment of US$110 million, along with potential milestone payments totaling US$1.185 billion.
Analysts at Huafu Securities expressed optimism that HMPL-A830 could carve out a niche in the KRAS-mutated colorectal cancer segment where current treatment options remain insufficient, given its differentiated mechanism of action. The brokerage advised investors to closely monitor the upcoming Phase I data readout as a key catalyst.
Meanwhile, Huatai Securities highlighted that the substantial licensing deal for A830 underscores the global value of HUTCHMED's ATTC platform. The firm anticipates that a global Phase I trial could commence as early as the second half of 2026, while the company's other pipeline candidates, A251 and A580, are also progressing smoothly through early-stage global development. With multiple molecules expected to enter clinical trials in succession, the brokerage believes the company's out-licensing momentum is set to continue.
Beyond the latest GSK agreement, HUTCHMED has already inked several significant business development deals with major multinational pharmaceutical companies, including AstraZeneca and Takeda. These earlier partnerships are now progressively translating into commercial value, with overseas sales of fruquintinib continuing to grow steadily. In addition, the global Phase III trial for savolitinib in second-line non-small cell lung cancer achieved positive results on both progression-free survival and overall survival endpoints during the eight-month period ending in May, positioning the drug for an imminent FDA filing.
Comments